×
Components:
Ketotifen Fumarate
Method of action:
Antiallergic, Anti-Asthmatic, Antihistamines For Systemic Use, Membrane Stabilizing, Ophthalmologic Agent, Ophthalmologicals
Available in countries
See all
close
Medically reviewed by Fedorchenko Olga Valeryevna, Pharmacy-Provisor. Last updated on 2019.12.06

Name of the medicinal product

Ketotifen WZF

Qualitative and quantitative composition

Ketotifen Fumarate

Therapeutic indications

The information provided in Therapeutic indications of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close
Capsule, hard; Eye drops, solution; Syrup
Ophthalmic solution; Solution-drops
Solution

Symptomatic treatment of seasonal allergic conjunctivitis.

Ketotifen WZF® (ketotifen fumarate ophthalmic solution) is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.

ZADITOR® (ketotifen fumarate ophthalmic solution) is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

Adults and children 3 years of age and older: Put 1 drop in the affected eye(s) twice daily, every 8-12 hours, no more than twice per day.

Children under 3 years of age: Consult a doctor.

Contraindications

The information provided in Contraindications of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close
Ophthalmic solution; Solution-drops
Solution

Ketotifen WZF® (ketotifen fumarate) is contraindicated in persons with a known hypersensitivity to any component of this product.

ZADITOR® (ketotifen fumarate) is contraindicated in persons with a known hypersensitivity to any component of this product.

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

WARNINGS

For topical ophthalmic use only. Not for injection or oral use.

PRECAUTIONS

See PATIENT INFORMATION section.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Ketotifen fumarate was determined to be non-mutagenic in a battery of in vitro and in vivo mutagenicity assays including: Ames test, in vitro chromosomal aberration test with V79 Chinese hamster cells, in vivo micronucleus assay in mouse, and mouse dominant lethal test.

Treatment of male rats with oral doses of ketotifen ³10 mg/kg/day orally [6,667 times the maximum recommended human ocular dose of 0.0015 mg/kg/day on a mg/kg basis (MRHOD)] for 70 days prior to mating resulted in mortality and a decrease in fertility. Treatment with ketotifen did not impair fertility in female rats receiving up to 50 mg/kg/day of ketotifen orally (33,333 times the MRHOD) for 15 days prior to mating.

Pregnancy

Pregnancy Category C

Oral treatment of pregnant rabbits during organogenesis with 45 mg/kg/day of ketotifen (30,000 times the MRHOD) resulted in an increased incidence of retarded ossification of the sternebrae. However, no effects were observed in rabbits treated with up to 15 mg/kg/day (10,000 times the MRHOD). Similar treatment of rats during organogenesis with 100 mg/kg/day of ketotifen (66,667 times the MRHOD) did not reveal any biologically relevant effects.

Oral treatment of pregnant rats (up to 100 mg/kg/day or 66,667 times the MRHOD) and rabbits (up to 45 mg/kg/day or 30,000 times the MRHOD) during organogenesis did not result in any biologically relevant embryofetal toxicity. In the offspring of the rats that received ketotifen orally from day 15 of pregnancy to day 21 post partum at 50 mg/kg/day (33,333 times the MRHOD), a maternally toxic treatment protocol, the incidence of postnatal mortality was slightly increased, and body weight gain during the first four days post partum was slightly decreased.

Nursing Mothers

Ketotifen fumarate has been identified in breast milk in rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, caution should be exercised when ketotifen fumarate is administered to a nursing mother.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

Effects on ability to drive and use machines

The information provided in Effects on ability to drive and use machines of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

Any patient who experiences blurred vision or somnolence should not drive or operate machines.

Undesirable effects

The information provided in Undesirable effects of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

In controlled clinical studies, conjunctival injection, headaches, and rhinitis were reported at an incidence of 10 to 25%. The occurrence of these side effects was generally mild. Some of these events were similar to the underlying ocular disease being studied.

The following ocular and non-ocular adverse reactions were reported at an incidence of less than 5%:

Ocular: Allergic reactions, burning or stinging, conjunctivitis, discharge, dry eyes, eye pain, eyelid disorder, itching, keratitis, lacrimation disorder, mydriasis, photophobia, and rash.

Non-Ocular: Flu syndrome, pharyngitis.

Overdose

The information provided in Overdose of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

Oral ingestion of the contents of a 5 mL bottle would be equivalent to 1.725 mg of ketotifen fumarate. Clinical results have shown no serious signs or symptoms after the ingestion of up to 20 mg of ketotifen fumarate.

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

Pharmacotherapeutic group: Ophthalmologicals, other antiallergics

ATC code: S01GX08

Ketotifen is a histamine H1-receptor antagonist. In vivo animal studies and in vitro studies suggest the additional activities of mast cell stabilisation and inhibition of infiltration, activation and degranulation of eosinophils.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

In a pharmacokinetic study conducted in 18 healthy volunteers with Zaditen eye drops, plasma levels of ketotifen after repeated ocular administration for 14 days were in most cases below the limit of quantitation (20pg/ml).

After oral administration, ketotifen is eliminated biphasically with an initial half-life of 3 to 5 hours and a terminal half-life of 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours and 60 to 70% as metabolites. The main metabolite is the practically inactive ketotifen-Nglucuronide.

Pharmacotherapeutic group

The information provided in Pharmacotherapeutic group of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close
Ophthalmologicals, other antiallergics

Preclinical safety data

The information provided in Preclinical safety data of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

Preclinical data reveal no special hazard which is considered relevant in connection with use of Zaditen eye drops in humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.

Incompatibilities

The information provided in Incompatibilities of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

Not applicable.

Special precautions for disposal and other handling

The information provided in Special precautions for disposal and other handling of Ketotifen WZF is based on data of another medicine with exactly the same composition as the Ketotifen WZF of the medicine (Ketotifen Fumarate). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug Ketotifen WZF directly from the package or from the pharmacist at the pharmacy.
more... close

No special requirements.

Site feedback

How easy to use our site?

Commentary is required, without it we won't know how to become better
The maximum length of review is 1000 symbols

Thanks!

You help us to become better